Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells

Colloidal gold nanoparticles are targeting probes to improve varlitinib delivery into cancer cells. The nanoconjugates were designed by the bioconjugation of pegylated gold nanoparticles with varlitinib via carbodiimide-mediated cross-linking and characterized by infrared and X-ray photoelectron spe...

Full description

Bibliographic Details
Main Authors:	Sílvia Castro Coelho, Daniel Pires Reis, Maria Carmo Pereira, Manuel A. N. Coelho
Format:	Article
Language:	English
Published:	MDPI AG 2018-07-01
Series:	Pharmaceutics
Subjects:	gold nanoparticles tyrosine conjugation pancreatic cells
Online Access:	http://www.mdpi.com/1999-4923/10/3/91

id	doaj-b1cbc4594fca4b148eb9aa910d01e766
record_format	Article
spelling	doaj-b1cbc4594fca4b148eb9aa910d01e7662020-11-25T00:56:45ZengMDPI AGPharmaceutics1999-49232018-07-011039110.3390/pharmaceutics10030091pharmaceutics10030091Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer CellsSílvia Castro Coelho0Daniel Pires Reis1Maria Carmo Pereira2Manuel A. N. Coelho3LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr Roberto Frias, 4200-465 Porto, PortugalLEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr Roberto Frias, 4200-465 Porto, PortugalLEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr Roberto Frias, 4200-465 Porto, PortugalLEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr Roberto Frias, 4200-465 Porto, PortugalColloidal gold nanoparticles are targeting probes to improve varlitinib delivery into cancer cells. The nanoconjugates were designed by the bioconjugation of pegylated gold nanoparticles with varlitinib via carbodiimide-mediated cross-linking and characterized by infrared and X-ray photoelectron spectroscopy. The drug release response shows an initial delay and a complete drug release after 72 h is detected. In vitro experiments with MIA PaCa-2 cells corroborate that PEGAuNPsVarl conjugates increase the varlitinib toxic effect at very low concentrations (IC50 = 80 nM) if compared with varlitinib alone (IC50 = 259 nM). Our results acknowledge a decrease of drug side effects in normal cells and an enhancement of drug efficacy against to the pancreatic cancer cells reported.http://www.mdpi.com/1999-4923/10/3/91gold nanoparticlestyrosine conjugationpancreatic cells
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Sílvia Castro Coelho Daniel Pires Reis Maria Carmo Pereira Manuel A. N. Coelho
spellingShingle	Sílvia Castro Coelho Daniel Pires Reis Maria Carmo Pereira Manuel A. N. Coelho Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells Pharmaceutics gold nanoparticles tyrosine conjugation pancreatic cells
author_facet	Sílvia Castro Coelho Daniel Pires Reis Maria Carmo Pereira Manuel A. N. Coelho
author_sort	Sílvia Castro Coelho
title	Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells
title_short	Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells
title_full	Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells
title_fullStr	Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells
title_full_unstemmed	Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells
title_sort	gold nanoparticles for targeting varlitinib to human pancreatic cancer cells
publisher	MDPI AG
series	Pharmaceutics
issn	1999-4923
publishDate	2018-07-01
description	Colloidal gold nanoparticles are targeting probes to improve varlitinib delivery into cancer cells. The nanoconjugates were designed by the bioconjugation of pegylated gold nanoparticles with varlitinib via carbodiimide-mediated cross-linking and characterized by infrared and X-ray photoelectron spectroscopy. The drug release response shows an initial delay and a complete drug release after 72 h is detected. In vitro experiments with MIA PaCa-2 cells corroborate that PEGAuNPsVarl conjugates increase the varlitinib toxic effect at very low concentrations (IC50 = 80 nM) if compared with varlitinib alone (IC50 = 259 nM). Our results acknowledge a decrease of drug side effects in normal cells and an enhancement of drug efficacy against to the pancreatic cancer cells reported.
topic	gold nanoparticles tyrosine conjugation pancreatic cells
url	http://www.mdpi.com/1999-4923/10/3/91
work_keys_str_mv	AT silviacastrocoelho goldnanoparticlesfortargetingvarlitinibtohumanpancreaticcancercells AT danielpiresreis goldnanoparticlesfortargetingvarlitinibtohumanpancreaticcancercells AT mariacarmopereira goldnanoparticlesfortargetingvarlitinibtohumanpancreaticcancercells AT manuelancoelho goldnanoparticlesfortargetingvarlitinibtohumanpancreaticcancercells
_version_	1725225716358840320

Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells

Similar Items